Position Statement of the Immunonephrology Working Group of the Portuguese Society of Nephrology on the Use of Belimumab in Lupus Nephritis
DOI:
https://doi.org/10.71749/pkj.89Keywords:
Antibodies, Monoclonal, Humanized/therapeutic use, Belimumab, Lupus Nephritis/drug therapyAbstract
Systemic lupus erythematosus (SLE) is a challenging immune ‑mediated disease that frequently involves the kidney as lupus nephritis (LN), an immune complex glomerulonephritis. Its occurrence is associated with increased morbidity and mortality and current treatment still fails to preserve renal function in the long term. As such, more efficacious and less toxic treatments are needed to treat LN, aiming to reduce renal relapses and improve renal survival. Belimumab, an inhibitor of the soluble B ‑cell activating factor became the first biologic agent approved for the treatment of SLE and is now approved as an add ‑on therapy for LN. Herein, the Immunonephrology Working Group of the Portuguese Society of Nephrology reviewed the scientific evidence that led to belimumab´s approval in recent LN guidelines and exposed its perspective on the use of belimumab in LN in Portugal.Downloads
References
- Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology. 2016;55:252–262. doi: 10.1093/rheumatology/kev311
- Wang H, Ren YL, Chang J, Gu L, Sun LY. A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis. Arch Rheumatol. 2017 Jul 25;33(1):17-25. doi: 10.5606/ArchRheumatol.2017.6127
- Luo W, Farinha F, Isenberg DA, Rahman A. Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40-years of follow-up. Rheumatology (Oxford) 2022;62:200–8. doi: 10.1093/rheumatology/keac218
- Farinha F, Barreira S, Couto M, Cunha M, Fonseca D, Freitas R, et al. Risk of chronic kidney disease in 260 patients with lupus nephritis-analysis of a nationwide multicentre cohort with up to 35 years of follow-up. Rheumatology (Oxford). 2024 Apr 22. doi: 10.1093/rheumatology/keae236
- Brad H Rovin, Isabelle M Ayoub, Tak Mao Chan, Zhi-Hong Liu, Juan Manuel Mejía-Vilet, Jürgen Floege. KDIGO 2024 Clinical Practice Guideline for the management of Lupus Nephritis. Kidney Int. 2024 Jan;105(1S):S1-S69. doi: 10.1016/j.kint.2023.09.002.
- Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83:15–29. doi: 10.1136/ard-2023-224762.
- Cragg MS, Walshe CA, Ivanov AO, Glennie MJ SO. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140
- Parodis I, Stockfelt M, Sjöwall C. B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. Front Med (Lausanne). 2020 Jul 9;7:316. doi: 10.1159/000082102.
- Belimumab resumo das características do medicamento https://ec.europa.eu/health/documents/communityregister/2017/20170320137420/anx_137420_pt.pdf
- Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. (2011) 377:721–31. doi: 10.1016/S0140-6736(10)61354-2.
- Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. (2011) 63:3918–30. doi: 10.1002/art.30613.
- Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. (2018) 77:355–63. doi: 10.1136/annrheumdis-2017-211631
- Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. (2017) 69:1016–27. doi: 10.1002/art.40049.
- Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol. (2018) 70:1256–64. doi: 10.1002/art.40511.
- D’Cruz D, Maksimowicz-McKinnon K, Oates J, Santiago MB, Bass D, Burriss S, et al. 200 Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study. Lupus Sci Med. (2019) 6:A149–50. DOI:10.1136/lupus-2019-lsm.200
-Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. (2017) 69:115–23. doi: 10.1002/acr.22971.
- Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, et al. Low disease activity-irrespective of serologic status at baseline- associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: a real-life observational study. Semin Arthritis Rheum. (2018) 48:467–74. doi: 10.1016/j.semarthrit.2018.02.014.
- Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180.
- Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015 May;67(5):1305-13. doi: 10.1002/art.39026.
- Anders HJ, Furie R, Malvar A, Zhao MH, Hiromura K, Weinmann-Menke J, et al. Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial. Nephrol Dial Transplant. 2023 Nov 30;38(12):2733-2742. doi: 10.1093/ndt/gfad167.
- Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022 Feb;101(2):403-413. doi: 10.1016/j.kint.2021.08.027.
- Furie R, Rovin BH, Houssiau F, Contreras G, Teng YKO, Curtis P, et al. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study. Clin J Am Soc Nephrol. 2022 Nov;17(11):1620-1630. doi: 10.2215/CJN.02520322.
- Huang SP, Snedecor SJ, Nanji S, Lloyd E, Bell CF. Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review. Rheumatol Ther. 2022 Aug;9(4):975-991. doi: 10.1007/s40744-022-00454-9.
- Tan M, Xu J, Tan Y, Qu Z, Yu F, Zhao M. Efficacy and Safety of Belimumab in Lupus Nephritis Patients: A Real-World Observational Study in China. Kidney Dis (Basel). 2023 Feb 14;9(3):218-228. doi: 10.1159/000529675.
Malvar A, Alberton V, Recalde C, Heguilen R. Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A “post-hoc” analysis of participants in the BLISS-LN and open label extension study belonging to a single center. Lupus. 2023 Oct;32(12):1394-1401. doi: 10.1177/09612033231204070
- Gatto M, Saccon F, Andreoli L, Bartoloni E, Benvenuti F, Bortoluzzi A, et al. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. Journal of Autoimmunity 124 (2021) 102729. doi: 10.1016/j.jaut.2021.102729.
- Relatório público de avaliação Benlysta (Belimumab) – Infarmed https://www.infarmed.pt/documents/15786/3368817/Relat%C3%B3rio+de+avalia%C3%A7%C3%A3o+de+financiamento+p%C3%BAblico+de+Benlysta+%28Belimumab%29/d988e284-ccc2-d83f-f3f1-f824222a12de
- Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80: 93–104 doi: 10.1038/ki.2010.531.
- Thompson A, Carroll K, Inker L, et al. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clin J Am Soc Nephrol 14: 469–481, 2019. doi: 10.2215/CJN.08600718.
- Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. J Am Soc Nephrol. 2009 May; 20(5): 1103–1112. doi: 10.1681/ASN.2008101028.
- Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011 Mar;63(3):351-7. doi: 10.1002/acr.20397.
- Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004 Dec;50(12):3934-40. doi: 10.1002/art.20666.
- FDA - Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure. https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure
- Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014 Dec;64(6):821-35. doi: 10.1053/j.ajkd.2014.07.030.
-Luís MSF, Bultink IEM, da Silva JAP, et al. Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. Rheumatology 2021; 60:5134-41. doi: 10.1093/rheumatology/keab126.
-Kapsia E, Marinaki S, Michelakis I, et al. Predictors of early response, flares, and long-term adverse renal outcomes in proliferative lupus nephritis: a 100-monthmedian follow-up of an inception cohort. J Clin Med 2022;11:5017. doi: 10.3390/jcm11175017.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Estela Nogueira, Nuno Oliveira, Iolanda Godinho, Alice Lança, António Inácio, Clara Santos, Helena Pinto, Ivo Laranjinha, Raquel Vaz, Sofia Oliveira Correia, Teresa Jerónimo, Inês Ferreira (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
